Responses
Therapeutics
Randomised controlled trial
For people with non-valvular atrial fibrillation rivaroxaban is non-inferior to warfarin for preventing stroke or embolism, with no difference in the risk of clinically relevant bleeding
Compose a Response to This Article
Other responses
No responses have been published for this article.